TASE:TEVA.TA

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

December 12, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) --…

2 weeks ago

Teva Releases Q4 2025 Aide Memoire

December 12, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) --…

2 weeks ago

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citis 2025 Global Healthcare Conference in December

November 21, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) --…

1 month ago

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

October 31, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) --…

2 months ago

FDA Approves Expanded Indication for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate…

2 months ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

September 25, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) --…

3 months ago

Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR®…

3 months ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…

3 months ago